Saltar al contenido
PivotalWire
Lunes 12 oct 2026SEC · NASDAQ biomédico

Portada›Viernes 14 de noviembre de 2025

Biomédicas del NASDAQ ante la SEC, viernes 14 de noviembre de 2025

Los 122 documentos que 74 empresas del sector presentaron ante la SEC ese día, agrupados por tipo y con el enlace al original en EDGAR.

·

El día, bloque a bloque

Va en color lo que cambia el capital o avisa de un riesgo: las emisiones con precio (424B1, 424B2, 424B4 y 424B5), los 8-K con item 1.02, 1.03, 2.04, 3.01, 3.02 y 4.02, y cualquier documento en el que haya aparecido una frase vigilada, que va citada debajo. Lo demás va en tinta normal. Una cita marcada «por primera vez» es una frase que no estaba en el informe previo del mismo tipo de esa empresa. La etiqueta del formulario lleva a su explicación.

Emisiones y dilución

  1. ABVCABVC BIOPHARMA, INC.424B4Nueva emisión de acciones con precioEDGAR
    En el documentoAviso de incumplimiento de las reglas de cotizacióntexto original ▸…took effect on July 25, 2023. Series A Convertible Preferred Stock As of September 30, 2025, no Series A Convertible Preferred Stock has been issued by the Company. NASDAQ Listing On May 24, 2023, we received a deficiency letter from the Nasdaq Listing Qualifications Department (the “Staff”) of the Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that it is not currently in compliance with the minimum stockholders’ equity…
    En el documentoContrasplit de accionestexto original ▸…Amendment to its Articles of Incorporation authorizing a 1-for-10 reverse stock split of the issued and outstanding shares of its common stock (the “2023 Split”). The Company’s stockholders previously approved the Reverse Stock Split at the Company’s Special Shareholder Meeting held on July 7, 2023. The Reverse Stock Split was effected to reduce the number of issued and outstanding shares and to increase the per share trading value…
  2. ABVCABVC BIOPHARMA, INC.424B4Nueva emisión de acciones con precioEDGAR
    En el documentoAviso de incumplimiento de las reglas de cotizacióntexto original ▸…took effect on July 25, 2023. Series A Convertible Preferred Stock As of September 30, 2025, no Series A Convertible Preferred Stock has been issued by the Company. NASDAQ Listing On May 24, 2023, we received a deficiency letter from the Nasdaq Listing Qualifications Department (the “Staff”) of the Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that it is not currently in compliance with the minimum stockholders’ equity…
    En el documentoContrasplit de accionestexto original ▸…Amendment to its Articles of Incorporation authorizing a 1-for-10 reverse stock split of the issued and outstanding shares of its common stock (the “2023 Split”). The Company’s stockholders previously approved the Reverse Stock Split at the Company’s Special Shareholder Meeting held on July 7, 2023. The Reverse Stock Split was effected to reduce the number of issued and outstanding shares and to increase the per share trading value…
  3. ABVCABVC BIOPHARMA, INC.424B4Nueva emisión de acciones con precioEDGAR
    En el documentoAviso de incumplimiento de las reglas de cotizacióntexto original ▸…took effect on July 25, 2023. Series A Convertible Preferred Stock As of September 30, 2025, no Series A Convertible Preferred Stock has been issued by the Company. NASDAQ Listing On May 24, 2023, we received a deficiency letter from the Nasdaq Listing Qualifications Department (the “Staff”) of the Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that it is not currently in compliance with the minimum stockholders’ equity…
    En el documentoContrasplit de accionestexto original ▸…Amendment to its Articles of Incorporation authorizing a 1-for-10 reverse stock split of the issued and outstanding shares of its common stock (the “2023 Split”). The Company’s stockholders previously approved the Reverse Stock Split at the Company’s Special Shareholder Meeting held on July 7, 2023. The Reverse Stock Split was effected to reduce the number of issued and outstanding shares and to increase the per share trading value…
  4. ABVCABVC BIOPHARMA, INC.424B4Nueva emisión de acciones con precioEDGAR
    En el documentoAviso de incumplimiento de las reglas de cotizacióntexto original ▸…took effect on July 25, 2023. Series A Convertible Preferred Stock As of September 30, 2025, no Series A Convertible Preferred Stock has been issued by the Company. NASDAQ Listing On May 24, 2023, we received a deficiency letter from the Nasdaq Listing Qualifications Department (the “Staff”) of the Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that it is not currently in compliance with the minimum stockholders’ equity…
    En el documentoContrasplit de accionestexto original ▸…Amendment to its Articles of Incorporation authorizing a 1-for-10 reverse stock split of the issued and outstanding shares of its common stock (the “2023 Split”). The Company’s stockholders previously approved the Reverse Stock Split at the Company’s Special Shareholder Meeting held on July 7, 2023. The Reverse Stock Split was effected to reduce the number of issued and outstanding shares and to increase the per share trading value…
  5. ENGNenGene Therapeutics Inc.424B5Nueva emisión de acciones con precioEDGAR
    En el documentoDuda sustancial sobre la continuidad de la empresatexto original ▸…activities for the year ended October 31, 2023, has an accumulated deficit at October 31, 2023, and will require additional financing in order to fund its future expected negative cash flows, that raise substantial doubt about its ability to continue as a going concern. The consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty. The financial statements of Forbion European Acquisition Corp. for the year…
  6. ENSCEnsysce Biosciences, Inc.424B5Nueva emisión de acciones con precioEDGAR
    En el documentoDuda sustancial sobre la continuidad de la empresatexto original ▸…the fourth quarter of 2025. The report of our independent registered public accounting firm on our financial statements for the years ended December 31, 2024 and 2023 contains explanatory language that substantial doubt exists about our ability to continue as a going concern. We have reduced expenses because we do not have access to sufficient cash and liquidity to finance our business operations as currently contemplated and may be compelled to reduce further general and…
  7. GRIGRI Bio, Inc.424B3Prospecto suplementario o de reventaEDGAR
    En el documentoDuda sustancial sobre la continuidad de la empresatexto original ▸…attempting to secure additional financing may divert the time and attention of management from day-to-day activities and distract from our discovery and product development efforts. As a result, there is substantial doubt about our ability to continue as a going concern. We expect to continue to incur significant and increasing operating losses at least for the foreseeable future. We do not expect to generate product revenue unless and until we successfully complete…
    En el documentoContrasplit de accionestexto original ▸…the treatment of autoimmune disorders, with much of its preclinical work in Systemic Lupus Erythematosus Disease or lupus and multiple sclerosis (MS). Recapitalization On January 29, 2024, the Company effected a reverse stock split of its common stock, par value $0.0001 per share (the Common Stock), at a ratio of one-for-seven (the January 2024 Reverse Stock Split). On June 17, 2024, the Company effected a reverse stock split of…
    En el documentoDebilidad material en el control internotexto original ▸…procedures were not effective as of September 30, 2025 due to the material weakness described in our Annual Report. In the course of preparing our financial statements for the Annual Report, management identified a material weakness related to the inaccurate computation of the non-cash deemed dividend associated with the re-pricing of the Series B Common Warrants in the Warrant Repricing Transaction in accordance with applicable…
    En el documentoPrograma de venta continua de acciones (ATM)texto original ▸…Common Stock, pre-funded warrants and common warrants in a public offering (the February 2024 Offering) for net proceeds of $4,389, after deducting offering expenses of $1,110. On May 20, 2024, the Company entered into an At The Market Offering Agreement (the Sales Agreement) with H.C. Wainwright & Co., LLC (Wainwright), pursuant to which the Company may sell and issue, subject to the limitations in the Sales Agreement, up to $10.0 million shares…
  8. JBIOJade Biosciences, Inc.S-1Capacidad de emisión registradaEDGAR
    En el documentoDuda sustancial sobre la continuidad de la empresatexto original ▸…results of its operations and its cash flows for the period from June 18, 2024 (inception) to December 31, 2024 in conformity with accounting principles generally accepted in the United States of America. Substantial Doubt about the Company’s Ability to Continue as a Going Concern The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 1 to the consolidated financial statements, the Company…
    En el documentoContrasplit de accionestexto original ▸…issued in the Pre-Closing Financing were converted into shares of Common Stock in accordance with the Exchange Ratio (as defined herein). 1 Immediately prior to the consummation of the Merger, Aerovate effected a 1-for-35 reverse stock split of Aerovate common stock (as defined herein), which became legally effective on April 28, 2025 (the “Reverse Stock Split”). Following the Reverse Stock Split, and as a result of and upon the First Effective…
  9. NEUPNeuphoria Therapeutics Inc.424B5Nueva emisión de acciones con precioEDGAR
    En el documentoPrograma de venta continua de acciones (ATM)texto original ▸…unchanged. This Amendment is not complete without, and may only be delivered or utilized in connection with, the Prospectus Supplement, and any future amendments or supplements hereto or thereto. We have entered into an At The Market Offering Agreement, or the Sales Agreement, with H.C. Wainwright & Co., LLC, or Wainwright, dated November 18, 2024. Under this Sales Agreement, as updated by this Amendment, we may offer and sell common stock…
  10. OMEROMEROS CORPS-3ASRCapacidad de emisión registradaEDGAR
    En el documentoDuda sustancial sobre la continuidad de la empresatexto original ▸…financial statements included in our Annual Report on Form 10-K for the year ended December 31, 2024, as set forth in their report (which contains an explanatory paragraph describing conditions that raise substantial doubt about the Company’s ability to continue as a going concern as described in Note 1 to the consolidated financial statements), which is incorporated by reference in this prospectus and elsewhere in the registration statement. Our financial statements are incorporated…
  11. OMEROMEROS CORP424B5Nueva emisión de acciones con precioEDGAR
    En el documentoDuda sustancial sobre la continuidad de la empresatexto original ▸…financial statements included in our Annual Report on Form 10-K for the year ended December 31, 2024, as set forth in their report (which contains an explanatory paragraph describing conditions that raise substantial doubt about the Company’s ability to continue as a going concern as described in Note 1 to the consolidated financial statements), which is incorporated by reference in this prospectus and elsewhere in the registration statement. Our financial statements are incorporated…
  12. ONMDOneMedNet Corp424B3Prospecto suplementario o de reventaEDGAR
    En el documentoDuda sustancial sobre la continuidad de la empresatexto original ▸…aggregate carrying value of $3.2 million. At the time of these settlements, (1) the Company had negative cash flow from operations, historical losses, and a significant accumulated deficit that raised substantial doubt about the Company’s ability to continue as a going concern, and (2) a concession was granted to the Company, as the fair value of the consideration received by the vendors was less than the net carrying value of the payables. As a result, the Company accounted…
  13. RNXTRenovoRx, Inc.424B5Nueva emisión de acciones con precioEDGAR
  14. SCLXScilex Holding Co424B3Prospecto suplementario o de reventaEDGAR
    En el documentoDuda sustancial sobre la continuidad de la empresatexto original ▸…its needs, successful completion of such plans is dependent on factors outside the Company’s control. As a result, management has concluded that the aforementioned conditions, among other things, raise substantial doubt about the Company’s ability to continue as a going concern for one year after the date the unaudited condensed consolidated financial statements are issued. 3. Acquisitions and License Agreements SP-104 Acquisition In May 2022, the Company acquired the Delayed…
    En el documentoContrasplit de accionestexto original ▸…Our Public Warrants are listed on the Nasdaq Capital Market under the symbol “SCLXW.” On November 13, 2025, the closing sale price per warrant of our Public Warrants was $0.22. On April 15, 2025, we effected a reverse stock split of our Common Stock at a ratio of 1-for-35 (the “Reverse Stock Split”). Unless otherwise noted, the share and per share information in the Prospectuses and this prospectus supplement reflects the effect…
    En el documentoPrograma de venta continua de acciones (ATM)texto original ▸…Credit Agreement) and the Subordination Agreement (each as defined in the eCapital Credit Agreement) were terminated, canceled and are of no further force and effect. On December 22, 2023, the Company entered into a Sales Agreement (the “ATM Sales Agreement”) with B. Riley Securities, Inc., Cantor Fitzgerald & Co. and H.C. Wainwright & Co., LLC (the “Sales Agents”), which agreement was voluntarily terminated by the Company effective as of March 5, 2025.…
  15. SCLXScilex Holding Co424B3Prospecto suplementario o de reventaEDGAR
    En el documentoDuda sustancial sobre la continuidad de la empresatexto original ▸…its needs, successful completion of such plans is dependent on factors outside the Company’s control. As a result, management has concluded that the aforementioned conditions, among other things, raise substantial doubt about the Company’s ability to continue as a going concern for one year after the date the unaudited condensed consolidated financial statements are issued. 3. Acquisitions and License Agreements SP-104 Acquisition In May 2022, the Company acquired the Delayed…
    En el documentoContrasplit de accionestexto original ▸…Our Public Warrants are listed on the Nasdaq Capital Market under the symbol “SCLXW.” On November 13, 2025, the closing sale price per warrant of our Public Warrants was $0.22. On April 15, 2025, we effected a reverse stock split of our Common Stock at a ratio of 1-for-35 (the “Reverse Stock Split”). Unless otherwise noted, the share and per share information in the Prospectuses and this prospectus supplement reflects the effect…
    En el documentoPrograma de venta continua de acciones (ATM)texto original ▸…Credit Agreement) and the Subordination Agreement (each as defined in the eCapital Credit Agreement) were terminated, canceled and are of no further force and effect. On December 22, 2023, the Company entered into a Sales Agreement (the “ATM Sales Agreement”) with B. Riley Securities, Inc., Cantor Fitzgerald & Co. and H.C. Wainwright & Co., LLC (the “Sales Agents”), which agreement was voluntarily terminated by the Company effective as of March 5, 2025.…
  16. SCLXScilex Holding Co424B3Prospecto suplementario o de reventaEDGAR
    En el documentoDuda sustancial sobre la continuidad de la empresatexto original ▸…its needs, successful completion of such plans is dependent on factors outside the Company’s control. As a result, management has concluded that the aforementioned conditions, among other things, raise substantial doubt about the Company’s ability to continue as a going concern for one year after the date the unaudited condensed consolidated financial statements are issued. 3. Acquisitions and License Agreements SP-104 Acquisition In May 2022, the Company acquired the Delayed…
    En el documentoContrasplit de accionestexto original ▸…Our Public Warrants are listed on the Nasdaq Capital Market under the symbol “SCLXW.” On November 13, 2025, the closing sale price per warrant of our Public Warrants was $0.22. On April 15, 2025, we effected a reverse stock split of our Common Stock at a ratio of 1-for-35 (the “Reverse Stock Split”). Unless otherwise noted, the share and per share information in the Prospectuses and this prospectus supplement reflects the effect…
    En el documentoPrograma de venta continua de acciones (ATM)texto original ▸…Credit Agreement) and the Subordination Agreement (each as defined in the eCapital Credit Agreement) were terminated, canceled and are of no further force and effect. On December 22, 2023, the Company entered into a Sales Agreement (the “ATM Sales Agreement”) with B. Riley Securities, Inc., Cantor Fitzgerald & Co. and H.C. Wainwright & Co., LLC (the “Sales Agents”), which agreement was voluntarily terminated by the Company effective as of March 5, 2025.…
  17. SRRKScholar Rock Holding Corp424B5Nueva emisión de acciones con precioEDGAR
    En el documentoDuda sustancial sobre la continuidad de la empresatexto original ▸…sufficient cash, cash equivalents and marketable securities to fund our operating expenses and capital requirements beyond one year from the date of this filing, and therefore, we have concluded that there is substantial doubt about our ability to continue as a going concern. Company Information We were incorporated in 2017 under the laws of the State of Delaware as the holding company for Scholar Rock, Inc. Scholar Rock, Inc. is a wholly owned subsidiary of Scholar Rock…
  18. UNCYUnicycive Therapeutics, Inc.424B5Nueva emisión de acciones con precioEDGAR
  19. BNTXBioNTech SE424B3Prospecto suplementario o de reventaEDGAR
  20. RNXTRenovoRx, Inc.S-3Capacidad de emisión registradaEDGAR
  21. TVGNTevogen Inc.424B3Prospecto suplementario o de reventaEDGAR

Participaciones y control

  1. ATRAAtara Biotherapeutics, Inc.SC 13D/ACambio en participación significativaEDGAR
  2. BBIOBridgeBio Pharma, Inc.SC 13D/ACambio en participación significativaEDGAR
  3. NCELNewcelX Ltd.SC 13DCambio en participación significativaEDGAR
  4. SVRASavara IncSC 13D/ACambio en participación significativaEDGAR
  5. TNGXTango Therapeutics, Inc.SC 13D/ACambio en participación significativaEDGAR
  6. VORVor Biopharma Inc.SC 13D/ACambio en participación significativaEDGAR

Informes y hechos relevantes

  1. ASBPAspire-Lakewood Holdings, Inc.8-KFin de acuerdo materialEDGAR
  2. BNTCBenitec Biopharma Inc.8-KResultadosEDGAR
    En el documentoDebilidad material en el control internotexto original ▸…sales, marketing, manufacturing and distribution requirements; greater than expected expenses; expenses relating to litigation or strategic activities; the impact of, and our ability to remediate, the identified material weakness in our internal controls over financial reporting; the impact of local, regional, and national and international economic conditions and events; and other risks detailed from time to time in the Company…
    En el documentoDesignación de medicamento huérfanotexto original ▸…protein. We believe the silence and replace mechanism of BB-301 is uniquely positioned for the treatment of OPMD by halting mutant expression while providing a functional replacement protein. BB-301 has received Orphan Drug Designation from the EMA and Orphan Drug and Fast Track Designations from the FDA. About Benitec Biopharma, Inc. Benitec Biopharma Inc. (“Benitec” or the “Company”) is a clinical-stage biotechnology company focused…
    En el documentoDesignación de vía rápida (Fast Track)texto original ▸EX-99.1 2 d811784dex991.htm EX-99.1 Exhibit 99.1 Benitec Biopharma Releases First Quarter 2026 Financial Results and Provides Operational Update -Fast Track Designation was granted for BB-301 following U.S. Food and Drug Administration (FDA) review of positive interim clinical study results and proprietary Responder Analysis planned for use in pivotal study for BB-301- -Positive…
  3. ENVBEnveric Biosciences, Inc.8-KResultadosEDGAR
    En el documentoContrasplit de accionestexto original ▸…Company from the exercise of the warrants were approximately $2.2 million, prior to deducting placement agent fees and estimated offering expenses ● After the end of the Third Quarter of 2025, the Company completed a reverse stock split of its common stock on October 28, 2025, at a ratio of 1 post-split share for every 12 pre-split shares. The Board determined the reverse split was in the best interest of the shareholders after receiving…
  4. INBXInhibrx Biosciences, Inc.8-KResultadosEDGAR
    En el documentoEl ensayo alcanzó su objetivo principaltexto original ▸…announced positive topline results from its registrational trial of ozekibart (INBRX-109) in chondrosarcoma and provided an update on its colorectal cancer and Ewing sarcoma expansion cohorts. •Ozekibart met its primary endpoint in chondrosarcoma, demonstrating a statistically significant and clinically meaningful improvement in median progression-free survival compared to placebo. •Key secondary endpoints reinforce the primary…
  5. JBIOJade Biosciences, Inc.8-KResultadosEDGAR
    En el documentoContrasplit de accionestexto original ▸…Merger”). Following the Merger, Second Merger Sub merged with and into Aerovate, and Aerovate changed its name to “Jade Biosciences, Inc.” Immediately prior to the consummation of the Merger, Aerovate effected a 1-for-35 reverse stock split of the common stock, par value $0.0001 per share, of Aerovate (“Company Common Stock”), which became effective on April 28, 2025. At the Closing, among other things, the shares of Pre-Merger Jade common…
  6. MDCXMedicus Pharma Ltd.8-KOtros hechos relevantesEDGAR
    En el documentoEl ensayo alcanzó su objetivo principaltexto original ▸…testosterone suppression. The study included 48 healthy male volunteers. In February 2023, Antev also completed a Phase 2a study in fifty (50) patients with advanced prostate cancer (APC), where Teverelix achieved the primary endpoint of greater than 90% probability of castration levels of testosterone suppression (97.5%) but the secondary endpoint of maintaining this rate above 90% was not met with the probability dropping to 82.5…
  7. QCLSQ/C TECHNOLOGIES, INC.8-KCambio en el consejo o la direcciónEDGAR
    En el documentoContrasplit de accionestexto original ▸…Incorporation, as amended (the “Charter”), to effect, at the discretion of the board of directors (the “Board”) of the Company but prior to the one-year anniversary of the date on which the reverse stock split is approved by the Company’s stockholders at the Special Meeting, a reverse stock split of all of the outstanding shares of Common Stock, at a ratio in the range of 1-for-2 to 1-for-250, with such ratio to be determined by the Board in its discretion and included in a public announcement…
  8. ADILADIAL PHARMACEUTICALS, INC.8-KResultadosEDGAR
  9. ALLRAllarity Therapeutics, Inc.10-QInforme trimestralEDGAR
    En el documentoContrasplit de accionestexto original ▸…Company,” “Allarity,” “we,” “us,” “our” and similar terms refer to Allarity Therapeutics, Inc., Allarity Therapeutics A/S (as predecessor) and its respective consolidated subsidiaries. On April 9, 2024, we effected a 1-for-20 reverse stock split of the shares of our common stock. On September 11, 2024, we effected a 1-for-30 reverse stock split of the shares of our common stock. All historical share and per share amounts reflected throughout…
    En el documentoDebilidad material en el control internotexto original ▸…made known to them by others within those entities, particularly during the period when this report was being prepared. Based upon that evaluation, our Chief Executive Officer and Chief Financial Officer concluded there to be a material weakness in internal control over financial reporting as of June 30, 2025 due to the material weaknesses described below. Plan to Remediate Material Weakness Management has identified material weaknesses in its…
    En el documentoPrograma de venta continua de acciones (ATM)texto original ▸…of $1.60 per prefunded warrant, for gross proceeds to the Company of approximately $2.5 million, before deducting $0.05 million in legal fees and expenses. ATM Facility On March 19, 2024, the Company entered into an At-The-Market Issuance Sales Agreement, as amended (the “Sales Agreement”) with Ascendiant Capital Markets, LLC (“Ascendiant”) pursuant to which, the Company may offer and sell, from time to time at its sole discretion, shares of its common…
  10. ANNXAnnexon, Inc.8-KNuevo acuerdo materialEDGAR
  11. ARTLARTELO BIOSCIENCES, INC.8-KCambio de estatutosEDGAR
  12. ASBPAspire-Lakewood Holdings, Inc.10-QInforme trimestralEDGAR
    En el documentoDuda sustancial sobre la continuidad de la empresatexto original ▸…accordance with Financial Accounting Standard Board (“FASB”) Accounting Standards Codification (“ASC”) Subtopic 205-40, “Going Concern,” management has determined that the Company’s liquidity condition raises substantial doubt about the Company’s ability to continue as a going concern through twelve months from the date these condensed consolidated financial statements are available to be issued. These condensed consolidated financial statements do not include any adjustments relating…
  13. ASBPAspire-Lakewood Holdings, Inc.10-Q/AInforme trimestral (enmienda)EDGAR
    En el documentoDuda sustancial sobre la continuidad de la empresatexto original ▸…accordance with Financial Accounting Standard Board (“FASB”) Accounting Standards Codification (“ASC”) Subtopic 205-40, “Going Concern,” management has determined that the Company’s liquidity condition raises substantial doubt about the Company’s ability to continue as a going concern through twelve months from the date these condensed consolidated financial statements are available to be issued. These condensed consolidated financial statements do not include any adjustments relating…
  14. AVXLANAVEX LIFE SCIENCES CORP.8-KOtros hechos relevantesEDGAR
  15. BFRGBullFrog AI Holdings, Inc.10-QInforme trimestralEDGAR
    En el documentoPrograma de venta continua de acciones (ATM)texto original ▸…registered direct offering of common stock and pre-funded warrants, and concurrent private placement of common stock warrants generating approximately $2.7 million of net proceeds. In April 2025, the Company entered into an ATM Agreement with BTIG, LLC, pursuant to which the Company may offer and sell shares of common stock, from time to time in its sole discretion, at the market price up to an aggregate offering price of $20 million…
  16. BIAFbioAffinity Technologies, Inc.8-KResultadosEDGAR
  17. BIAFbioAffinity Technologies, Inc.10-QInforme trimestralEDGAR
    En el documentoDuda sustancial sobre la continuidad de la empresatexto original ▸…approximately $7.7 million. Based on the Company’s current expected level of operating expenditures and the cash and cash equivalents on hand at September 30, 2025, management concludes that there is substantial doubt about the Company’s ability to continue as a going concern for a period of at least twelve (12) months subsequent to the issuance of the accompanying unaudited condensed consolidated financial statements. During the third quarter of 2025, the Company completed…
  18. BNTCBenitec Biopharma Inc.10-QInforme trimestralEDGAR
    En el documentoContrasplit de accionestexto original ▸…of common stock from 40,000,000 to 160,000,000. The Charter Amendment was filed with the Secretary of State of the State of Delaware and became effective December 9, 2022. On July 26, 2023, the Company effected a 1-for-17 reverse stock split (the “Reverse Stock Split”) . On October 11, 2024, the Company entered into a Sales Agreement (the “Sales Agreement”) with Leerink Partners LLC (the “Agent”). Pursuant to the terms of the Sales Agreement…
    En el documentoDebilidad material en el control internotexto original ▸…sales, marketing, manufacturing and distribution requirements; • greater than expected expenses, expenses relating to litigation or strategic activities; • the impact of, and our ability to remediate, the identified material weakness in our internal controls over financial reporting; 3 Table of Contents • our ability to satisfy our capital needs through increasing revenue and obtaining additional financing; and • the impact of local…
  19. CELUCelularity Inc10-QInforme trimestralEDGAR
    En el documentoDuda sustancial sobre la continuidad de la empresatexto original ▸…Company to strategic or financial investors, and/or allowing the Company to become insolvent by filing for bankruptcy protection under the provisions of the U.S. Bankruptcy Code. These uncertainties raise substantial doubt about the Company’s ability to continue as a going concern. The accompanying condensed consolidated financial statements have been prepared on the basis that the Company will continue to operate as a going concern, which contemplates that the Company will be…
    En el documentoPrograma de venta continua de acciones (ATM)texto original ▸…Celularity or the removal of existing management. As of September 30, 2025 and December 31, 2024, the Company did not have any outstanding preferred stock. ATM Agreement On September 8, 2022, the Company entered into an At-the-Market Sales Agreement (the “ATM Agreement”) with BTIG, LLC, Oppenheimer & Co. Inc. and B. Riley Securities, Inc., acting as sales agents and/or principals, pursuant to which the Company may offer and sell, from time to time…
  20. CGONCG Oncology, Inc.8-KResultadosEDGAR
  21. CGONCG Oncology, Inc.10-QInforme trimestralEDGAR
  22. CGONCG Oncology, Inc.8-KCambio en el consejo o la direcciónEDGAR
  23. CNSPCNS Pharmaceuticals, Inc.10-QInforme trimestralEDGAR
    En el documentoDuda sustancial sobre la continuidad de la empresatexto original ▸…report negative cash flows from operations and a net loss. Management believes that the cash on hand is sufficient to fund its planned operations into but not beyond the near term. These factors raise substantial doubt regarding the Company’s ability to continue as a going concern. These financial statements do not include any adjustments to the recoverability and classification of recorded asset amounts and classification of liabilities that might be necessary should the Company…
    En el documentoContrasplit de accionestexto original ▸…change in the par value per share, which remained at $0.001. The reverse stock split has been retroactively adjusted throughout these financial statements and footnotes. On July 22, 2025, the Company effected a reverse stock split on a 1-for-12 basis without any change in the par value per share, which remained at $0.001. The reverse stock split has been retroactively adjusted throughout these financial statements and footnotes…
    En el documentoPrograma de venta continua de acciones (ATM)texto original ▸…the par value per share, which remained at $0.001. The reverse stock split has been retroactively adjusted throughout these financial statements and footnotes. Common Stock On July 26, 2024, the Company entered into a Sales Agreement (the “AGP ATM Sales Agreement”) with A.G.P./Alliance Global Partners (“AGP”). Pursuant to the terms of the AGP ATM Sales Agreement, the Company originally was permitted to sell from time to time through AGP, as sales agent or principal…
  24. COCPCocrystal Pharma, Inc.10-QInforme trimestralEDGAR
    En el documentoDuda sustancial sobre la continuidad de la empresatexto original ▸…inception. For the nine months ended September 30, 2025, the Company recorded a net loss of approximately $6,405,000 and used approximately $6,456,000of cash in operating activities. These factors raise substantial doubt about the Company’s ability to continue as a going concern. On September 30, 2025, the Company had cash and restricted cash of approximately $7,804,000. Restricted cash represents amounts pledged as collateral for financing arrangements that are currently limited…
  25. COCPCocrystal Pharma, Inc.8-KResultadosEDGAR
  26. CYTKCYTOKINETICS INC8-KCambio en el consejo o la direcciónEDGAR
  27. DCOYDecoy Therapeutics Inc.10-QInforme trimestralEDGAR
    En el documentoDuda sustancial sobre la continuidad de la empresatexto original ▸…product sales to date and has suffered recurring losses from operations since its inception. The lack of revenue from product sales to date and recurring losses from operations since its inception raise substantial doubt as to the Company's ability to continue as a going concern. The accompanying financial statements are prepared using accounting principles generally accepted in the United States applicable to a going concern, which contemplates the realization of assets and…
    En el documentoContrasplit de accionestexto original ▸…Bid Price Requirement. However, pursuant to Nasdaq listing rule 5810(c)(3)(A)(iv), Salarius is not eligible for any compliance period specified in Nasdaq listing rule 5810(c)(3)(A) because Salarius has effected a reverse stock split during the prior one-year period. In addition, as previously disclosed, on March 26, 2025, Salarius received a letter from Nasdaq notifying Salarius that, based on the financial statements contained in…
    En el documentoPrograma de venta continua de acciones (ATM)texto original ▸…accounts payable and note payable approximate their fair values due to the short-term nature of these instruments. NOTE 6. STOCKHOLDERS' EQUITY Common Stock Issuances On February 5, 2021, the Company entered into an At the Market Offering Agreement ("ATM") with Ladenburg Thalmann & Co. Inc. Under this agreement the Company is able to issue and sell, from time to time, shares of its common stock. During the nine months ended September 30…
  28. DRMADermata Therapeutics, Inc.8-KResultadosEDGAR
  29. DRMADermata Therapeutics, Inc.10-QInforme trimestralEDGAR
    En el documentoDuda sustancial sobre la continuidad de la empresatexto original ▸…date of this filing. While the Company plans to launch its first product candidate in mid-2026, it is uncertain when the Company will generate operating income to sustain operations. These factors raise substantial doubt about the Company’s ability to continue as a going concern for the one-year period following the date that these financial statements were issued. Historically, the Company’s principal sources of cash have included proceeds from the issuance of equity securities…
    En el documentoContrasplit de accionestexto original ▸…Company’s board of directors without further approval or authorization of its stockholders. On August 1, 2025, the Company effected the reverse split of its shares of Common Stock at a ratio of 1-for-10, as approved by the Company’s board of directors (the “2025 Reverse Stock Split”). The par value was not adjusted as a result of the 2025 Reverse Stock Split. All issued and outstanding shares of Common Stock and per share amounts contained in the financial statements have been retroactively…
    En el documentoPrograma de venta continua de acciones (ATM)texto original ▸…Funded Warrants remained outstanding, which were exercised during the first quarter of 2025. As of September 30, 2025, no September 2024 Pre-Funded Warrants remained outstanding. In June 2024, the Company entered into an At The Market Offering Agreement (the “ATM Agreement”) with a sales agent (the “Sales Agent”), providing for the sale of up to $1,157,761 of its shares of Common Stock as set forth in the ATM Agreement. The Sales Agent will…
  30. ELABPMGC Holdings Inc.10-QInforme trimestralEDGAR
    En el documentoDuda sustancial sobre la continuidad de la empresatexto original ▸…2025, and 2024, the Company incurred a net loss of $4,765,130 and $4,310,998, respectively and used $4,183,881 and $3,486,435, respectively of cash flows for operating activities. These factors raise substantial doubt regarding the Company’s ability to continue as a going concern. These unaudited condensed consolidated financial statements do not include any adjustments to the recoverability and classification of recorded asset amounts and classification of liabilities that might…
    En el documentoContrasplit de accionestexto original ▸…Skincare. On November 13, 2024, PMGC Capital LLC (“PMGC Capital”) was incorporated under the laws of the state of Nevada, PMGC is the sole shareholder of PMGC Capital. On November 27, 2024, the Company completed a reverse stock split on a ratio of two hundred old shares of common stock for every one new post reverse split share of common stock. On March 10, 2025, the Company completed a second reverse stock split on a ratio of seven…
  31. ELDNEledon Pharmaceuticals, Inc.10-QInforme trimestralEDGAR
    En el documentoDebilidad material en el control internotexto original ▸…Our principal executive officer and principal financial officer have evaluated the effectiveness of our disclosure controls and procedures as of September 30, 2025, and, based on this evaluation, have concluded that due to the material weakness in our internal control over financial reporting previously identified in Part II, Item 9A of our Annual Report on Form 10-K/A for the year ended December 31, 2024, our disclosure controls and procedures…
  32. ELDNEledon Pharmaceuticals, Inc.8-KResultadosEDGAR
  33. ENGNenGene Therapeutics Inc.8-KNuevo acuerdo materialEDGAR
  34. ENSCEnsysce Biosciences, Inc.8-KResultadosEDGAR
  35. ENSCEnsysce Biosciences, Inc.10-QInforme trimestralEDGAR
    En el documentoDuda sustancial sobre la continuidad de la empresatexto original ▸…necessary to develop the Company’s products and will require significant additional financing. There can be no assurance the Company will be able to obtain such funds. These matters, among others, raise substantial doubt about the Company’s ability to continue as a going concern. While the Company believes in the viability of its strategy to ultimately realize revenues and in its ability to raise additional funds, management cannot be certain that additional funding will be available…
  36. ENTXEntera Bio Ltd.8-KResultadosEDGAR
  37. ENTXEntera Bio Ltd.10-QInforme trimestralEDGAR
    En el documentoDuda sustancial sobre la continuidad de la empresatexto original ▸…ENTERA BIO LTD. NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (U.S. dollars in thousands, except share and per share data) (Unaudited) NOTE 1 - DESCRIPTION OF BUSINESS (Cont.) These factors raise substantial doubt as to the Company's ability to continue as a going concern. Management continually evaluates various financing alternatives and strategic collaborations, as the Company will need to finance future research and clinical development with additional capital. However…
  38. ENVBEnveric Biosciences, Inc.8-KOtros hechos relevantesEDGAR
  39. ENVBEnveric Biosciences, Inc.10-QInforme trimestralEDGAR
    En el documentoDuda sustancial sobre la continuidad de la empresatexto original ▸…not yet generated revenue and the Company has incurred continuing losses from its operations. The Company’s operations have been funded principally through the issuance of equity. These factors raise substantial doubt about the Company’s ability to continue as a going concern for a period of one year from the issuance of these unaudited condensed consolidated financial statements. 6 ENVERIC BIOSCIENCES, INC. AND SUBSIDIARIES NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS…
    En el documentoAviso de incumplimiento de las reglas de cotizacióntexto original ▸…issuance costs. The Company also incurred legal and other offering-related fees of $334,659, which were similarly charged to additional paid-in capital. Nasdaq Listing On August 26, 2025, the Company received a deficiency letter from the Listing Qualifications Department (the “Staff”) of Nasdaq notifying the Company that it was not in compliance with the minimum stockholders’ equity requirement for continued listing on the Nasdaq…
    En el documentoContrasplit de accionestexto original ▸…EVM301 Series. The Company’s next step is to advance EB-003 into formal preclinical development studies in support of a future Investigational New Drug (“IND”) filing. Reverse Stock Splits The Company effected a 1-for-15 reverse stock split (“Reverse Stock Split”) on January 27, 2025, which began trading on a split-adjusted basis on January 29, 2025, pursuant to which every 15 shares of the Company’s issued and outstanding common stock,…
    En el documentoPrograma de venta continua de acciones (ATM)texto original ▸…earnings per share, the deemed dividend was also recorded as an increase in net loss available to common stockholders for purposes of calculating net loss per share. At the Market Offering The Company entered into an at the market offering agreement, or the (“ATM Agreement”), with H.C. Wainwright & Co., LLC, or (“Wainwright”), acting as sales agent, on April 9, 2025, relating to shares of Common Stock. Under the ATM Agreement, the Company…
  40. FBIOFortress Biotech, Inc.8-KResultadosEDGAR
    En el documentoDesignación de medicamento huérfanotexto original ▸…, “us” and “our” may refer to Fortress individually, to one or more of our subsidiaries and/or partner companies, or to all such entities as a group, as dictated by context. ​ ● In July 2025, the FDA granted Orphan Drug Designation to Mustang Bio, Inc. (“Mustang Bio”) for MB-101 (IL13Ra2-targeted CAR T-cells) for the treatment of recurrent diffuse and anaplastic astrocytoma and glioblastoma. MB-101 received Orphan Drug Designation…
  41. FBIOFortress Biotech, Inc.10-QInforme trimestralEDGAR
    En el documentoContrasplit de accionestexto original ▸…for its manufacturing facility in Worcester, Massachusetts and sold certain fixed assets including furniture and equipment to AbbVie Bioresearch Center, Inc. for $1.0 million. ● In January 2025, Mustang effected a 1-for-50 reverse stock split to achieve compliance with the minimum bid price listing requirement of the Nasdaq Capital Market. ​ Critical Accounting Policies and Use of Estimates Our discussion and analysis of our financial condition…
    En el documentoPrograma de venta continua de acciones (ATM)texto original ▸…date of a Form 25 with the SEC; Avenue is therefore ineligible to use Form S-3 and unable to use the Avenue 2021 S-3 or the Avenue Replacement Shelf. Avenue At the Market Offering In May 2024, Avenue entered into an At-the-Market Offering Agreement (the “Avenue ATM”) under which Avenue was able to offer and sell, from time to time at its sole discretion, up to $3.9 million of shares of its common stock. The offers and sales of the shares…
  42. FBRXForte Biosciences, Inc.8-KResultadosEDGAR
  43. FBRXForte Biosciences, Inc.10-QInforme trimestralEDGAR
    En el documentoContrasplit de accionestexto original ▸…The Company's headquarters is in Dallas, Texas. The Company’s common stock is traded on the Nasdaq stock exchange under the ticker symbol “FBRX”‌. Reverse Stock Split On August 27, 2024, the Company effected a 1-for-25 reverse stock split of its issued and outstanding common stock. The par value and authorized shares were not adjusted as a result of the reverse split. The reverse stock split also affected the Company’s outstanding common…
    En el documentoDebilidad material en el control internotexto original ▸…management efforts. Forte may experience difficulty in meeting these reporting requirements in a timely manner. During the audit process related to Forte’s fiscal year ended December 31, 2022, management identified a material weakness in Forte’s controls related to the review of the annual income tax provision which had been prepared by a third-party accounting firm that has since been remediated. A material weakness is a deficiency…
  44. FTHFaeth Therapeutics, Inc.8-KResultadosEDGAR
    En el documentoRecorte de plantilla o reestructuracióntexto original ▸…licensing arrangements, collaborations, a sale of the Company, a business combination, a merger, or an orderly wind-down of operations. In connection with this strategic review, the Company has implemented a workforce reduction to preserve cash, reducing its workforce by approximately 65 percent. The Company is retaining a small team of employees to assist in exploring strategic alternatives, maintaining compliance with regulatory…
  45. FTHFaeth Therapeutics, Inc.10-QInforme trimestralEDGAR
    En el documentoDuda sustancial sobre la continuidad de la empresatexto original ▸…equivalents to fund its operating expenses and capital requirements within one year from the issuance of these condensed consolidated financial statements, and therefore, the Company has concluded that there is substantial doubt about its ability to continue as a going concern. The accompanying condensed consolidated financial statements have been prepared on the basis that the Company will continue to operate as a going concern, which contemplates it will be able to realize…
    En el documentoContrasplit de accionestexto original ▸…condensed consolidated financial statements do not include any adjustments that may result from the outcome of these uncertainties. Reverse stock split On June 16, 2025, at 5:00 p.m. Eastern Time, the Company effected a 1-for-20 reverse stock split of the Company’s issued and outstanding shares of common stock (the “Reverse Stock Split”) and a corresponding reduction in the total number of authorized shares of its common stock from 250,000,000 shares…
  46. GALTGALECTIN THERAPEUTICS INC10-QInforme trimestralEDGAR
    En el documentoDuda sustancial sobre la continuidad de la empresatexto original ▸…GAAP) assuming the Company will continue as a going concern. The going concern assumption contemplates the realization of assets and satisfaction of liabilities in the normal course of business. However, substantial doubt about the Company’s ability to continue as a going concern exists. The Company has operated at a loss since its inception and has had no revenues. The Company anticipates that losses will continue for the foreseeable future. At September 30, 2025, the company…
  47. GALTGALECTIN THERAPEUTICS INC8-KResultadosEDGAR
  48. GLSIGreenwich LifeSciences, Inc.10-QInforme trimestralEDGAR
    En el documentoDuda sustancial sobre la continuidad de la empresatexto original ▸…its assets and satisfy its liabilities in the normal course of business. However, the Company has incurred net losses since its inception and has negative operating cash flows. These circumstances raise substantial doubt about the Company’s ability to continue as a going concern. The accompanying financial statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classifications of liabilities…
  49. GNPXGenprex, Inc.10-QInforme trimestralEDGAR
    En el documentoDuda sustancial sobre la continuidad de la empresatexto original ▸…additional financing to fund its operating and capital requirements, there is uncertainty regarding the Company’s ability to maintain liquidity sufficient to operate its business effectively, which raises substantial doubt as to the Company’s ability to continue as a going concern. These unaudited condensed consolidated financial statements do not include any adjustments that might be necessary if Genprex is unable to continue as a going concern. 8 Table of Contents GENPREX, INC…
    En el documentoContrasplit de accionestexto original ▸…changed this accounting principle to expense, rather than capitalize, these intellectual property costs on the basis that the new treatment is favorable. Reverse Stock Split On February 2, 2024, Genprex completed a 1-for-40 reverse stock split (“2024 Reverse Split”) of its issued and outstanding shares of common stock. The 2024 Reverse Split did not change the number of authorized shares of common stock or par value. All references in these…
    En el documentoPrograma de venta continua de acciones (ATM)texto original ▸…of the March 2024 offering. As of December 31, 2024, all of the 27,543 March 2024 Pre-Funded Warrants had been exercised for shares of common stock. At-The-Market Offering On December 13, 2023, Genprex entered into an At The Market (“ATM”) Offering Agreement (the “Sales Agreement”) with H.C. Wainwright & Co., LLC, serving as agent (the “Agent”) with respect to an at-the-market offering program (the “2023 ATM Facility”) under which the Company may…
  50. GRIGRI Bio, Inc.10-QInforme trimestralEDGAR
    En el documentoDuda sustancial sobre la continuidad de la empresatexto original ▸…attempting to secure additional financing may divert the time and attention of management from day-to-day activities and distract from our discovery and product development efforts. As a result, there is substantial doubt about our ability to continue as a going concern. We expect to continue to incur significant and increasing operating losses at least for the foreseeable future. We do not expect to generate product revenue unless and until we successfully complete…
    En el documentoContrasplit de accionestexto original ▸…the treatment of autoimmune disorders, with much of its preclinical work in Systemic Lupus Erythematosus Disease or lupus and multiple sclerosis (MS). Recapitalization On January 29, 2024, the Company effected a reverse stock split of its common stock, par value $0.0001 per share (the Common Stock), at a ratio of one-for-seven (the January 2024 Reverse Stock Split). On June 17, 2024, the Company effected a reverse stock split of…
    En el documentoDebilidad material en el control internotexto original ▸…procedures were not effective as of September 30, 2025 due to the material weakness described in our Annual Report. In the course of preparing our financial statements for the Annual Report, management identified a material weakness related to the inaccurate computation of the non-cash deemed dividend associated with the re-pricing of the Series B Common Warrants in the Warrant Repricing Transaction in accordance with applicable…
    En el documentoPrograma de venta continua de acciones (ATM)texto original ▸…Common Stock, pre-funded warrants and common warrants in a public offering (the February 2024 Offering) for net proceeds of $4,389, after deducting offering expenses of $1,110. On May 20, 2024, the Company entered into an At The Market Offering Agreement (the Sales Agreement) with H.C. Wainwright & Co., LLC (Wainwright), pursuant to which the Company may sell and issue, subject to the limitations in the Sales Agreement, up to $10.0 million shares…
  51. GTBPGT Biopharma, Inc.8-KResultadosEDGAR
  52. GTBPGT Biopharma, Inc.10-QInforme trimestralEDGAR
    En el documentoDuda sustancial sobre la continuidad de la empresatexto original ▸…collaborations. For the nine months ended September 30, 2025, the Company recorded a net loss of approximately $5.3million and used cash in operations of approximately $8.9 million. These factors raise substantial doubt about the Company’s ability to continue as a going concern within one year of the date that the financial statements are issued. In addition, the Company’s independent registered public accounting firm, in its report on the Company’s December 31, 2024, financial…
  53. HCWBHCW Biologics Inc.8-KResultadosEDGAR
  54. HCWBHCW Biologics Inc.10-QInforme trimestralEDGAR
    En el documentoDuda sustancial sobre la continuidad de la empresatexto original ▸…implemented within one year after the date that the financial statements are issued, and (2) it is probable that the plans, when implemented, will mitigate the relevant conditions or events that raise substantial doubt about the entity’s ability to continue as a going concern within one year after the date that the financial statements are issued. As of September 30, 2025, the Company had not generated any revenue from commercial product sales of its internally developed immunotherapeutic…
    En el documentoContrasplit de accionestexto original ▸…Florida and was incorporated in the state of Delaware in April 2018. Reverse Stock Split On March 31, 2025, at a Special Meeting of the Stockholders (the “Special Meeting”), the stockholders of the Company approved a reverse stock split of all outstanding shares of the Common Stock, and the Board approved a reverse stock split of the Common Stock at a final ratio of one-for-forty (1::40) (the “Reverse Stock Split”). The Reverse Stock…
  55. HINDVyome Holdings, Inc10-QInforme trimestralEDGAR
    En el documentoContrasplit de accionestexto original ▸…Accounting Standards Codification (“ASC”) and Accounting Standards Updates (“ASU”) promulgated by the Financial Accounting Standards Board (“FASB”). In August 2025, the Board of Directors of the Company approved a 5,000: 1 reverse stock split. All share and per share numbers have been updated to reflect such a reverse stock split. b) Segments The Company organized its operations into two operating segments. The segments reflect the way the…
  56. HURATuHURA Biosciences, Inc./NV8-KResultadosEDGAR
    En el documentoPrograma de venta continua de acciones (ATM)texto original ▸…Alkermes, Ventus Therapeutics and Third Harmonic Bio. • $50 Million At-The-Market (ATM) Facility Filed. In November 2025, TuHURA became eligible to file a “shelf” registration statement on Form S-3 and entered into agreement providing for an ATM facility of up to $50 Million. TuHURA will become able to sell shares under the ATM facility when the S-3 registration statement filed on November 3, 2025 becomes effective under the rules and regulations of the…
  57. HURATuHURA Biosciences, Inc./NV10-QInforme trimestralEDGAR
    En el documentoPrograma de venta continua de acciones (ATM)texto original ▸…financial statements, which is the date they were available to be issued. Registration Statement on Form S-3 and ATM Offering On November 3, 2025, the Company and H.C. Wainwright & Co., LLC (“Wainwright”) entered into an At-The-Market Offering Agreement (the “Offering Agreement”) with respect to an at-the-market offering program under which the Company may sell shares of its common stock having an aggregate offering price of up to $50,000,000through…
  58. HYPDHYPERION DEFI, INC.10-QInforme trimestralEDGAR
    En el documentoDuda sustancial sobre la continuidad de la empresatexto original ▸…strategic treasury of HYPE. The Company also extended the maturity date of its Loan and Security Agreement (see Note 8 – Notes Payable and Convertible Notes Payable). These actions have alleviated the substantial doubt about the Company’s ability to continue as a going concern that existed at the time the Company filed its December 31, 2024 Form 10-K. As of September 30, 2025, the Company had unrestricted cash and cash equivalents of approximately $8.2 million and working capital…
    En el documentoContrasplit de accionestexto original ▸…number of outstanding shares of the registrant’s common stock was8,097,659 as of November 10, 2025. ​ ​ ​ ​ Table of Contents EXPLANATORY NOTE On January 31, 2025, Hyperion DeFi, Inc. (the “Company”) effected a reverse stock split of its common stock at a ratio of 1-for-80 (the “Reverse Split”). Upon the effectiveness of the Reverse Split, every 80 issued shares of common stock were reclassified and combined into one share of common…
  59. IKTInhibikase Therapeutics, Inc.8-KResultadosEDGAR
  60. IKTInhibikase Therapeutics, Inc.10-QInforme trimestralEDGAR
  61. INBXInhibrx Biosciences, Inc.10-QInforme trimestralEDGAR
  62. INKTMiNK Therapeutics, Inc.10-QInforme trimestralEDGAR
    En el documentoDuda sustancial sobre la continuidad de la empresatexto original ▸…more than one year from when these financial statements were issued. Because the completion of anticipated funding is not entirely within the Company’s control, the Company is required to disclose that substantial doubt exists about its ability to continue as a going concern for a period of one year after the date of filing of this Quarterly Report on Form 10-Q. The financial statements have been prepared on a basis that assumes MiNK will continue as a going concern and which…
  63. IXHLIncannex Healthcare Inc.10-QInforme trimestralEDGAR
    En el documentoDebilidad material en el control internotexto original ▸…financial reporting, such that there is a reasonable possibility that a material misstatement of our annual or interim financial statements will not be prevented or detected on a timely basis. Management has concluded that we did not maintain effective disclosure controls and procedures due to the material weakness in internal control over financial reporting which existed as of September 30, 2025, relating to the documentation of accounting policies and procedures, particularly relating to the correct application…
  64. JAGXJaguar Health, Inc.10-QInforme trimestralEDGAR
    En el documentoPrograma de venta continua de acciones (ATM)texto original ▸…retroactively adjusted to give effect to the reverse stock split for all periods presented, unless indicated otherwise. At the Market Offering (“ATM”) December 2021 ATM Agreement On December 10, 2021, the Company entered into an ATM Agreement (as amended, the “December 2021 ATM Agreement”) with Ladenburg, pursuant to which the Company may offer and sell, from time to time through Ladenburg, shares of common stock having an aggregate offering…
  65. JAGXJaguar Health, Inc.8-KNuevo acuerdo materialEDGAR
  66. JBIOJade Biosciences, Inc.10-QInforme trimestralEDGAR
    En el documentoContrasplit de accionestexto original ▸…of Company common stock and pre-funded warrants to purchase Company common stock in accordance with the Exchange Ratio. Reverse Stock Split Immediately prior to the consummation of the Merger, Aerovate effected a 1-for-35 reverse stock split of Aerovate common stock, which became legally effective on April 28, 2025 (the “Reverse Stock Split”). The Company common stock commenced trading on a post-Reverse Stock Split, post-Merger basis at the…
  67. JUNSJUPITER NEUROSCIENCES, INC.10-QInforme trimestralEDGAR
    En el documentoDuda sustancial sobre la continuidad de la empresatexto original ▸…price of our common stock could be subject to rapid and substantial volatility; and ● Our management’s assessment of historical losses, negative cash flows, and reliance on private equity financing raises substantial doubt about our ability to continue as a going concern, as noted in our auditor’s reports for 2023 and 2024. Should one or more of these risks or uncertainties materialize, or should any of our assumptions prove incorrect, actual results may vary in material…
  68. LIMNLiminatus Pharma, Inc.10-QInforme trimestralEDGAR
    En el documentoDuda sustancial sobre la continuidad de la empresatexto original ▸…of going concern considerations in accordance with Financial Accounting Standards Board (“FASB”) ASC 205-40, Presentation of Financial Statements—Going Concern, management has concluded that there is substantial doubt about its ability to continue as a going concern for one year after the date that the accompanying unaudited condensed consolidated financial statements are issued. The Company’s unaudited condensed consolidated financial statements do not include any…
  69. LITSLite Strategy, Inc.10-QInforme trimestralEDGAR
  70. LNAILunai Bioworks Inc.10-QInforme trimestralEDGAR
    En el documentoDuda sustancial sobre la continuidad de la empresatexto original ▸…operations. As of September 30, 2025, the Company had cash and cash equivalents of $624,808, an accumulated deficit of $507,643,549 and a working capital deficit of $18,922,114. These conditions raise substantial doubt about the Company’s ability to continue as a going concern for one year after the date the financial statements are issued. The consolidated financial statements do not include any adjustments relating to the recoverability and classification of recorded asset…
    En el documentoDebilidad material en el control internotexto original ▸…complex accounting matters. This control deficiency will be monitored, and attention will be given to this matter as we grow. The Certifying Officers based their conclusion on the fact that the Company has identified a material weakness in controls over financial reporting, detailed above. We expect to be deficient in our disclosure controls and procedures until sufficient capital is available to hire the appropriate internal accounting…
  71. MDCXMedicus Pharma Ltd.10-QInforme trimestralEDGAR
    En el documentoDuda sustancial sobre la continuidad de la empresatexto original ▸…future products, which are critical to the realization of its business plan and the future operations of the Company. This uncertainty, along with the Company's history of losses, indicates that there is substantial doubt about the Company's ability to continue as a going concern within one year after the date that the financial statements are issued. The accompanying condensed consolidated financial statements do not include any adjustments that may be necessary should the Company…
  72. MRKRMarker Therapeutics, Inc.8-KResultadosEDGAR
  73. NEUPNeuphoria Therapeutics Inc.10-QInforme trimestralEDGAR
  74. NRXPNRX Pharmaceuticals, Inc.10-QInforme trimestralEDGAR
    En el documentoDuda sustancial sobre la continuidad de la empresatexto original ▸…operations. The Company will continue to carefully monitor the impact of its continuing operations on the Company’s working capital needs and debt repayment obligations. As such, the Company has concluded that substantial doubt exists regarding the Company’s ability to continue as a going concern for a period of at least twelve months from the date of issuance of these condensed consolidated financial statements. The accompanying condensed consolidated financial statements have been prepared on…
  75. NTHINEONC TECHNOLOGIES HOLDINGS, INC.10-QInforme trimestralEDGAR
    En el documentoDuda sustancial sobre la continuidad de la empresatexto original ▸…The report of our independent registered public accounting firm on our financial statements as of and for the year ended December 31, 2024 included an explanatory paragraph indicating that there was substantial doubt about our ability to continue as a going concern. See Note 1 to our financial statements for additional information on our assessment. Components of Results of Operations Revenue We occasionally receive a fee from a patient for a “right to try” humanitarian…
  76. NTHINEONC TECHNOLOGIES HOLDINGS, INC.8-KResultadosEDGAR
    En el documentoCambio en la dirección de la empresatexto original ▸…exposure to institutional investors. ● Strong IP Protection – Global patent portfolio spans all major pharmaceutical markets, covering the company’s core CNS oncology assets. ● Executive Leadership – Appointed Amir Heshmatpour as Chief Executive Officer to Drive Next Phase of Clinical and Corporate Growth ● Scientific Leadership - Appointed leading neuro-oncologists Dr. David M. Ashley (Duke University), Dr. Alexandra M. Miller (NYU Langone Health),…
  77. ONMDOneMedNet Corp10-QInforme trimestralEDGAR
    En el documentoDuda sustancial sobre la continuidad de la empresatexto original ▸…aggregate carrying value of $3.2 million. At the time of these settlements, (1) the Company had negative cash flow from operations, historical losses, and a significant accumulated deficit that raised substantial doubt about the Company’s ability to continue as a going concern, and (2) a concession was granted to the Company, as the fair value of the consideration received by the vendors was less than the net carrying value of the payables. As a result, the Company accounted…
  78. PPCBPropanc Biopharma, Inc.10-QInforme trimestralEDGAR
    En el documentoDuda sustancial sobre la continuidad de la empresatexto original ▸…and had net cash used in operations of $1,939,067. Additionally, As of September 30, 2025, the Company had accumulated deficit of $130,459,258. It is management’s opinion that these conditions raise substantial doubt about the Company’s ability to continue as a going concern for a period of at least twelve months from the issue date of this Quarterly Report. The unaudited condensed consolidated financial statements do not include any adjustments to reflect the possible future…
  79. PTNPALATIN TECHNOLOGIES INC10-QInforme trimestralEDGAR
  80. RNAZTranscode Therapeutics, Inc.10-QInforme trimestralEDGAR
    En el documentoDuda sustancial sobre la continuidad de la empresatexto original ▸…realization of assets and liquidation of liabilities in the ordinary course of business. Due to the Company’s recurring and expected continuing losses from operations, the Company has concluded there is substantial doubt concerning its ability to continue as a going concern within one year of the issuance of these financial statements without additional capital becoming available. These financial statements do not include any adjustments that might result from the outcome…
  81. RNTXRein Therapeutics, Inc.10-QInforme trimestralEDGAR
    En el documentoDuda sustancial sobre la continuidad de la empresatexto original ▸…and commercialize LTI-03, including the potential benefits thereof; • our ability to secure sufficient additional capital in the near term or implement other strategies needed to alleviate our current substantial doubt about our ability to continue as a going concern; • our expectations regarding our ability to fund our operating expenses, our planned activities, and capital expenditure requirements with our cash, cash equivalents and investments • our Phase 2 clinical…
    En el documentoPrograma de venta continua de acciones (ATM)texto original ▸…gross proceeds for the Private Placement were $500. The Warrant Exercises, Warrant Exchanges and Private Placement are collectively referred to as the April 2025 Transactions. On May 15, 2025, the Company entered into an “at the market offering” agreement, or the Wainwright Sales Agreement, with H.C. Wainwright & Co., LLC, or H.C. Wainwright, as agent and/or principal, pursuant to which the Company could offer and sell shares of its common stock…
  82. RNXTRenovoRx, Inc.8-KNuevo acuerdo materialEDGAR
  83. SABSSAB Biotherapeutics, Inc.10-QInforme trimestralEDGAR
  84. SCLXScilex Holding Co10-QInforme trimestralEDGAR
    En el documentoDuda sustancial sobre la continuidad de la empresatexto original ▸…its needs, successful completion of such plans is dependent on factors outside the Company’s control. As a result, management has concluded that the aforementioned conditions, among other things, raise substantial doubt about the Company’s ability to continue as a going concern for one year after the date the unaudited condensed consolidated financial statements are issued. 3. Acquisitions and License Agreements SP-104 Acquisition In May 2022, the Company acquired the Delayed…
    En el documentoContrasplit de accionestexto original ▸…necessarily indicative of the results to be expected for the year ending December 31, 2025 or for any future periods. Reverse Stock Split On April 3, 2025, the Board of Directors of the Company (the “Board”) approved a reverse stock split of the Common Stock at a ratio of 1-for-35 (the “Reverse Stock Split”), which was effected on April 15, 2025. As a result of the Reverse Stock Split, every 35 shares of pre-Reverse Stock Split Common…
    En el documentoPrograma de venta continua de acciones (ATM)texto original ▸…Credit Agreement) and the Subordination Agreement (each as defined in the eCapital Credit Agreement) were terminated, canceled and are of no further force and effect. On December 22, 2023, the Company entered into a Sales Agreement (the “ATM Sales Agreement”) with B. Riley Securities, Inc., Cantor Fitzgerald & Co. and H.C. Wainwright & Co., LLC (the “Sales Agents”), which agreement was voluntarily terminated by the Company effective as of March 5, 2025.…
  85. SRRKScholar Rock Holding Corp8-KResultadosEDGAR
  86. SRRKScholar Rock Holding Corp10-QInforme trimestralEDGAR
  87. SRRKScholar Rock Holding Corp8-KOtros hechos relevantesEDGAR
  88. TCRTAlaunos Therapeutics, Inc.10-QInforme trimestralEDGAR
    En el documentoDuda sustancial sobre la continuidad de la empresatexto original ▸…has determined that the Company's present capital resources will not be sufficient to fund its planned operations for at least one year from the issuance date of the condensed financial statements, and substantial doubt as to the Company's ability to continue as a going concern exists. This forecast of cash resources is forward-looking information that involves risks and uncertainties, and the actual amount of expenses could vary materially and adversely as a result of a number…
    En el documentoDebilidad material en el control internotexto original ▸…the Company’s limited cash runway and ongoing operating losses, there can be no assurance that the Company will maintain compliance with Nasdaq’s continued listing requirements in the future. • We have identified a material weakness and failed to maintain an effective internal control environment, which may result in material misstatements of our financial statements or have a material adverse effect on our business or stock price…
  89. TVGNTevogen Inc.10-QInforme trimestralEDGAR
  90. TWSTTwist Bioscience Corp8-KResultadosEDGAR
  91. UNCYUnicycive Therapeutics, Inc.8-KOtros hechos relevantesEDGAR
  92. VBIOValion Bio, Inc.8-KResultadosEDGAR
    En el documentoDesignación de vía rápida (Fast Track)texto original ▸…of extensive trials for the treatment of acute radiation syndrome (ARS), and has demonstrated robust survival, enhanced GI tract recovery and improved hematopoiesis in animal models. Entolimod has been granted Fast Track Designation for ARS. About Tivic Health Systems, Inc. Tivic’s dual platform utilizes the body’s biopharmaceutical and bioelectronic systems to treat unmet medical needs through targeting the immune system. Tivic…
  93. VBIOValion Bio, Inc.10-QInforme trimestralEDGAR
    En el documentoDuda sustancial sobre la continuidad de la empresatexto original ▸…million. During the nine months ended September 30, 2025 and 2024, the Company had negative cash flows from operations of $4.7 million and $4.4 million, respectively. The aforementioned factors raise substantial doubt about the Company’s ability to continue as a going concern within one year from the issuance date of the financial statements. The accompanying financial statements have been prepared on a going concern basis, which contemplates the realization of assets and…
    En el documentoContrasplit de accionestexto original ▸…could be significantly delayed or limited, which could materially adversely affect its business, financial conditions, or results of operations. Reverse Stock Split Effective March 7, 2025, the Company implemented a reverse stock split of its issued and outstanding shares of common stock, par value $0.0001 per share, at a ratio of 1-for-17. As a result of the reverse stock split, the total number of shares of common stock held by each…
  94. VRCAVerrica Pharmaceuticals Inc.8-KResultadosEDGAR
  95. VRCAVerrica Pharmaceuticals Inc.10-QInforme trimestralEDGAR
    En el documentoDuda sustancial sobre la continuidad de la empresatexto original ▸…additional funding and considering its debt obligations, including a requirement to maintain cash, cash equivalents and investments of at least $10.0 million at all times, the Company has concluded that substantial doubt exists regarding its ability to continue as a going concern within one year after the date these financial statements are issued. The Company plans to address the conditions that raise substantial doubt regarding its ability to continue as a going concern by,…
    En el documentoContrasplit de accionestexto original ▸…VP-102) topical solution for the treatment of molluscum contagiosum in adult and pediatric patients two years of age and older. Reverse Stock Split At the close of trading on July 24, 2025, the Company effected a reverse stock split at a ratio of 1-for-10 shares of its common stock. As a result, every ten shares of the Company’s issued and outstanding common stock were automatically combined into one share. The reverse stock split…

·

Esto mismo, cada mañana y solo de tus empresas. Sigue a las que te interesen y recibe en tu correo lo que presenten ante la SEC, en castellano. Crear una cuenta. ¿Ya tienes cuenta? Entrar.

Esto no son recomendaciones de inversión. Son hechos públicos verificables en su fuente. Lee siempre el documento original antes de decidir nada. Aviso legal.